Phosphatidylinositol 4-kinase (Plasmodium falciparum) (PfPI4K)

Plasmodium falciparum phosphatidylinositol 4-kinase (PfPI4K) is a critical lipid kinase essential for the survival and development of the malaria parasite across all stages of its life cycle, including the liver, blood, and mosquito transmission stages (McNamara et al., Nature 2013). It functions by phosphorylating phosphatidylinositol to produce phosphatidylinositol 4-phosphate (PI4P), a key signaling molecule and structural component required for Golgi-mediated trafficking and the biogenesis of new plasma membranes during parasite replication or schizogony (UniProt Q8I4U0). Because PfPI4K is indispensable for the parasite but distinct enough from human PI4K isoforms, it has emerged as a high-priority target for next-generation antimalarial drugs. Several small-molecule inhibitors, such as ganaplacide (KAF156) and MMV390048, have demonstrated potent activity by binding to the ATP-binding pocket of the enzyme, leading to the collapse of internal membrane structures and parasite death (Paquet et al., Sci Transl Med 2017). Clinical development of these inhibitors focuses on their potential for single-dose cures and their ability to block transmission, though monitoring for resistance-conferring mutations remains a priority for therapeutic longevity.

Other names

PfPI4KPhosphatidylinositol 4-kinase type III beta homologPI4KIIIbetaP. falciparum PI4K

Inhibition of phosphatidylinositol 4-kinase activity, which depletes phosphatidylinositol 4-phosphate (PI4P) levels, disrupting intracellular membrane trafficking and preventing parasite development across multiple life cycle stages (McNamara et al., Nature 2013).